Drug Discovery

Drug discovery is the work of finding molecules that can safely change the course of a disease, and of proving that they do.

13 frameworks, from 50 to today · Pharmacology · Medicine & Health

still a working view ended · each leads to its entry below

Overview

Drug discovery is the work of finding molecules that can safely change the course of a disease, and of proving that they do. It is older than any of its component sciences: people were testing plants, minerals, and poisons on the sick long before anyone could say what a molecule was. What has changed across its history is not the goal but the method—how a discoverer decides where to look, and how much can be known before the first patient is dosed. That shift, from collecting remedies to designing molecules against a chosen biological target, is the spine of the story.

Materia medica: remedies collected and catalogued

For most of recorded history, drug discovery meant materia medica—the accumulated body of substances used as medicines, with their preparations, doses, and reputed effects. The Greek physician Dioscorides compiled a De materia medica in the first century CE that described some six hundred plants and other substances and remained a working reference for centuries1. Chinese, Indian, Islamic, and European traditions each built their own pharmacopoeias, and the knowledge travelled: opium, cinchona bark, digitalis, and willow bark entered practice through such collections, often with little understanding of why they worked.

The materia medica approach had a real strength—it preserved hard-won empirical observations—and a structural weakness: it could not distinguish an active substance from the bulk of a plant, could not standardize a dose, and could not explain an effect. Those limits set the agenda for the next two centuries.

Isolating the active principle

The first great turning point was chemical. If a plant worked, the reasoning went, some specific compound in it must be responsible. In the early nineteenth century, chemists learned to extract and purify such compounds: morphine was isolated from opium by Friedrich Sertürner around 1804–1806, and quinine from cinchona bark by Pierre-Joseph Pelletier and Joseph Caventou in 1820. Alkaloid chemistry followed, and with it the idea of a pure drug whose dose could be measured in milligrams rather than in handfuls of leaf.

Isolation made standardization possible and made pharmacology a laboratory science, but it also exposed a new problem: knowing a compound's structure did not reveal what it did in the body, or to which tissue.

Receptors, targets, and the magic bullet

Around 1900, Paul Ehrlich proposed that drugs act not on organs in general but on specific chemical structures in cells—receptors—and coined the term magic bullet for a drug that would strike a disease-causing agent while sparing the patient. Ehrlich's own work on arsenicals against syphilis, culminating in Salvarsan (arsphenamine) in 1909, was the first great demonstration that a synthetic chemical could be aimed at a defined target23. In parallel, John Newport Langley's experiments on nicotine and curare suggested that drugs acted at specific receptive sites, and later A. J. Clark's quantitative work in the 1920s and 1930s formalized the idea that a drug's effect depends on how much of a receptor it occupies.

Receptor theory gave drug discovery its modern question—what is the target, and how tightly does the drug bind it?—and made the search for new drugs a search for molecules with the right shape and affinity.

Systematic screening and the rise of pharmacokinetics

From the 1930s onward, discovery increasingly meant screening: testing many compounds against a biological assay and keeping the ones that work. This was systematic empirical screening, and it produced a remarkable run of drugs—sulfonamides, penicillin and the antibiotic era, antihypertensives, and many others. The approach did not require knowing the target; it required a reliable assay and a large collection of compounds.

A second strand matured alongside it: pharmacokinetics, the study of what the body does to a drug—absorption, distribution, metabolism, and excretion, often abbreviated ADME4. By the 1960s and 1970s it was clear that a compound could be potent in a test tube and useless in a patient because it was poorly absorbed, rapidly destroyed by the liver, or unable to reach its target. ADME optimization became a routine part of discovery, and later computational and in vitro screens were built to predict these properties before a compound was ever given to an animal.

Rational design and structure–activity relationships

The next turning point was the deliberate use of molecular structure. Structure–activity relationship (SAR) work—systematically varying a molecule's chemical groups and measuring how potency changes—became a standard tool, and it allowed chemists to improve a lead compound step by step56. The antihistamine and beta-blocker programs of the mid-twentieth century were built this way.

Rational drug design went further: start from knowledge of the target's three-dimensional structure and design a molecule to fit it7. The classic early case is the work of Gertrude Elion and George Hitchings at Burroughs Wellcome in the 1950s, who reasoned from the biochemistry of nucleic acid synthesis to design antimetabolites—6-mercaptopurine and later azathioprine and allopurinol—that interfered with specific enzymatic steps. Captopril, approved in 1981, was designed from knowledge of the angiotensin-converting enzyme. Rational design made the target, not the compound library, the starting point.

High-throughput screening and combinatorial chemistry

In the 1990s, automation and chemistry converged. Combinatorial chemistry allowed chemists to synthesize vast libraries of related compounds at once, and high-throughput screening (HTS) allowed robotic assays to test hundreds of thousands of compounds per run. The promise was that sheer scale would find hits faster than design could. In practice, the era produced fewer new drugs than hoped—libraries were often poorly suited to drug-like chemistry, and hits frequently failed later—but it permanently changed the infrastructure of discovery and pushed the field toward better libraries and better assays.

Fragments, genomics, and the return to structure

Two responses to the limits of HTS shaped the 2000s. Fragment-based drug discovery started from very small molecules that bind weakly to a target and then grew or linked them into potent drugs; it proved especially valuable for targets that resisted conventional screening. Separately, the sequencing of the human genome, announced in 2001, promised a flood of new targets—genomics-driven target discovery. The promise was real but slower than expected: a gene identifies a protein, not necessarily a good drug target, and validating a target takes years.

Pharmacogenomics: the patient enters the picture

A parallel line of work asked why the same drug helps one patient and harms another. Pharmacogenomics—the study of how genetic variation affects drug response—grew from mid-twentieth-century observations of inherited differences in drug metabolism, such as the differing rates at which people acetylate isoniazid, and matured with molecular genetics. It gave discovery a new consideration: a drug might be developed alongside a genetic test that identifies the patients likely to benefit, the companion diagnostic. This moved the field from "does the drug work?" toward "in whom does it work?"

Computational and AI-driven discovery

The most recent turn is computational. Machine learning models now predict binding, toxicity, and ADME properties, and generative methods propose new molecular structures; the field calls this AI-driven drug discovery. The approach descends directly from earlier computational chemistry and from the data generated by HTS and structural biology. Its promise is to shorten the search; its open question is whether predictions made in silico survive the transition to real assays and real patients.

Where the field stands

Today's discovery pipelines combine most of these strands: a target chosen from genetics or disease biology, screening and fragment methods to find starting points, structure-based design and SAR to optimize potency, ADME and toxicity prediction to filter candidates, and increasingly pharmacogenomic thinking to define the right patient population5. The unresolved questions are the old ones in new form—how to validate a target before investing years in it, how to predict human toxicity from animal and cellular data, and how to make computational predictions trustworthy enough to replace experiments. The history of drug discovery is, in the end, a history of learning to ask sharper questions of molecules before trusting them with patients.

References

  1. De materia medica, Wikipedia
  2. Magic bullet (medicine), Wikipedia
  3. Paul Ehrlich, Wikipedia
  4. ADME, Wikipedia
  5. Drug discovery (Screening and design, introduction), Wikipedia
  6. Structure–activity relationship, Wikipedia
  7. Drug design (Rational drug discovery, Structure-based), Wikipedia

The frameworks of Drug Discovery

Each framework is a way of working the field has used: when it held, and the question it answers.

  1. 50-1850

    Materia medica

    Which natural substances cure disease?

    Fly to its tower in Nousfarer

  2. 1805-1930

    Active-principle isolation

    Which compound in a remedy does the work?

    Fly to its tower in Nousfarer

  3. 1900-Present

    Receptor theory

    Where in the cell do drugs act?

    Fly to its tower in Nousfarer

  4. 1909-1945

    Magic-bullet chemotherapy

    How can a drug hit the germ and spare the patient?

    Fly to its tower in Nousfarer

  5. 1935-1990

    Systematic empirical screening

    Which compound works in a biological test?

    Fly to its tower in Nousfarer

  6. 1950-Present

    Rational drug design

    How do we design a molecule to fit a target?

    Fly to its tower in Nousfarer

  7. 1950-Present

    Structure–activity relationship

    How does changing a molecule change its potency?

    Fly to its tower in Nousfarer

  8. 1955-Present

    Pharmacogenomics

    Why does the same drug affect people differently?

    Fly to its tower in Nousfarer

  9. 1960-Present

    ADME

    What does the body do to a drug?

    Fly to its tower in Nousfarer

  10. 1990-2010

    Combinatorial chemistry and high-throughput screening

    Can testing vast numbers of compounds find drugs faster?

    Fly to its tower in Nousfarer

  11. 2000-Present

    Fragment-based lead discovery

    Can tiny weakly binding pieces be grown into drugs?

    Fly to its tower in Nousfarer

  12. 2001-Present
  13. 2010-Present

    Computational and AI-driven drug discovery

    Can computers predict which molecules will work?

    Fly to its tower in Nousfarer

How the ideas connect

Each arrow runs from an earlier idea to the later one it shaped. The list below says what passed between them.

Materia medicaActive-principle isolationReceptor theoryMagic-bullet chemotherapySystematic empirical screeningRational drug designStructure–activity relationshipPharmacogenomicsADMECombinatorial chemistry and high-thro…Fragment-based lead discoveryGenomics-driven target discoveryComputational and AI-driven drug disc…

Beyond the field

Where Drug Discovery's ideas came from in other fields, and what they led to there: the strongest 12 of 96 links.

A city in Nousfarer: a red-carpeted stair climbing terraces to a crowned tower on an acropolis, more towers round it, forest and snowy mountains beyond.
A city in Nousfarer, the game played in the browser.

Drug Discovery is a planet in Nousfarer

Its city has a tower for each of these 13 frameworks. Land, walk in, and climb one concept at a time.

Land on Drug Discovery

Related fields

Fields its ideas are linked to

More in Pharmacology

See where Drug Discovery sits on the Map of Human Knowledge